Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$10.18
-$0.43(-1.58%)
At close: 4:00 PM EST
$10.18
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$4.68 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)937.93K
Market Cap
$161.79M
Enterprise Value$29.17
Total Cash (Recent Filing)$258.38M
Total Debt (Recent Filing)$673.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 19, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding31,354,395
10 Day Avg. Volume1,293,719
30 Day Avg. Volume937,935
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.20Price Target Upside216.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.5
Revenue Forecast (FY)$18.69M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsSustained ~90% gross margins indicate robust per-unit economics that scale with volume. Strong product margins reduce the revenue required to reach profitability, allow pricing and promotional flexibility, and improve operating leverage over time if adoption continues.
Early Commercial Traction And Prescriber BaseMeaningful early prescription growth and a large prescriber footprint create a durable foundation for recurring sales. A broad and increasingly productive prescriber base reduces marginal marketing costs over time and supports scalable refill volumes as cohorts mature.
Strong Cash Position And Low LeverageA large cash balance and negligible debt provide strategic runway to fund commercialization and operational improvements without immediate financing. Conservative leverage increases flexibility for investments, partnerships or to absorb execution setbacks during launch scaling.
Bears Say
Large Negative Operating And Free Cash FlowPersistent negative operating and free cash flow requires ongoing external capital unless revenue scales rapidly. Continued cash consumption constrains flexibility, heightens dilution risk, and forces prioritization of near-term commercial spend over long-term investments unless burn meaningfully declines.
High SG&A And Operating LossesElevated SG&A relative to nascent revenue shows fixed-cost intensity from the launch. Unless revenue growth outpaces operating expense increases, reaching breakeven will require substantial and sustained volume gains, making profitability timing sensitive to commercialization execution.
Uncertain Refill Dynamics And Adoption PaceDurable revenue depends on refill persistence and routine prescribing. Lack of granular cohort refill data and slower new-patient adoption create uncertainty in lifetime value, complicate forecasting, and may require sustained promotional spend to overcome physician behavior barriers.
LENZ Therapeutics News
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $4.68 and its highest was $50.40 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $161.79M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 27 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.048 by -$0.272.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -1.05.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 31,354,395 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.048. Following the earnings report the stock price went down -20.821%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (216.31% Upside)
$32.20 (216.31% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.42%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Stock 12 Month Forecast
Average Price Target
$32.20
▲(216.31% Upside)
Technical Analysis
Ownership Overview
15.24% Insiders
15.87% Mutual Funds
0.07% Other Institutional Investors
59.98% Public Companies and
Individual Investors